Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +2.07%56 Equity-to-Asset is 0.89 as of Jun. 2026, which is 7% above its 10-year median of 0.83. GuruFocus rates BGLC with a GF Score™ of 56/100 and a GF Value™ of $1.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,622 Chemicals companies, BioNexus Gene Lab ranks better than 94.51% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioNexus Gene Lab's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $7.78 Mil. BioNexus Gene Lab's Total Assets for the quarter that ended in Jun. 2026 was $8.73 Mil.
Therefore, BioNexus Gene Lab's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.89.
The historical rank and industry rank for BioNexus Gene Lab's Equity-to-Asset or its related term are showing as below:
BGLC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.66 Med: 0.83 Max: 0.93
Current: 0.89
During the past 8 years, the highest Equity to Asset Ratio of BioNexus Gene Lab was 0.93. The lowest was 0.66. And the median was 0.83.
BGLC's Equity-to-Asset is ranked better than 94.51% of 1622
companies
in the Chemicals industry
Industry Median: 0.6
vs BGLC: 0.89
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioNexus Gene Lab Equity-to-Asset Related Terms
BioNexus Gene Lab Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs CNEY, SNES, QGAI: Equity-to-Asset Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Equity-to-Asset vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioNexus Gene Lab's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Equity-to-Asset of 0.89 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioNexus Gene Lab and its competitors. This is near median its historical median of 0.83. Over the past decade, BioNexus Gene Lab's Equity-to-Asset has ranged from 0.66 to 0.93. According to the industry distribution chart, BioNexus Gene Lab ranks #89 out of 1622 companies in the Chemicals industry, placing it in the top 5.5%.
Is BioNexus Gene Lab's Equity-to-Asset too high?
BioNexus Gene Lab's current Equity-to-Asset of 0.89 is near median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 0.93. The Chemicals industry median Equity-to-Asset is 0.60. BioNexus Gene Lab's value of 0.89 is 48.3% above this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #89 out of 1622 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Equity-to-Asset compare to CNEY and SNES?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #89 out of 1622 companies for Equity-to-Asset. This places BioNexus Gene Lab in the top 6% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. BioNexus Gene Lab's value of 0.89 is 48.3% above this benchmark. Historically, BioNexus Gene Lab's own Equity-to-Asset has ranged from 0.66 to 0.93 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 0.60, BioNexus Gene Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Chemicals company?
The median Equity-to-Asset among Chemicals companies is 0.60, based on 1,622 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Equity-to-Asset of 0.89 is 48.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Equity-to-Asset is 0.89, which is near median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.24, compared to a current price of $1.48 — trading 19.4% above its estimated fair value. The current Equity-to-Asset is 0.89, which is near median its 10-year median of 0.83 and 48.3% above the Chemicals industry median of 0.60. BioNexus Gene Lab's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Equity-to-Asset is 0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.48 is trading 19.4% above its estimated GF Value™ of $1.24.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
Equity-to-Asset: 0.89 (near median its 10-year median of 0.83)
GF Value™: $1.24 vs. price of $1.48 (19.4% above fair value)
Industry Position: 48.3% above the Chemicals median (#89 of 1622)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
56GF Score
Get the complete analysis for BGLC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
